segetoside I

from Vaccaria segetalis; structure in first source

Also Known As:

28-O-beta-D-xylopyranosyl-(1->4)-alpha-L-rhamnopyranosyl-(1->2)-(alpha-L-(5-O-acetyl)-arabinofuranosyl-(1->3))-beta-D-(4-O-acetyl)-fucopyranosyl-quillaic acid-3-O-beta-D-galactopyranosyl-(1->2)-beta-D-glucuronopyranoside

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Triterpenes: 2493
      - Pentacyclic Triterpenes: 108
        Oleanolic Acid: 547
        segetoside I: 1
      - Sapogenins: 26
        Oleanolic Acid: 547
        segetoside I: 1
Carbohydrates: 22023
- Glycosides: 2119
  - Saponins: 2867
    - segetoside I: 1

Experts

1.	Cao, Xia: 1 article (01/2016)
2.	Chen, Jingjing: 1 article (01/2016)
3.	Deng, Wenwen: 1 article (01/2016)
4.	Firempong, Caleb Kesse: 1 article (01/2016)
5.	Tong, Shan-Shan: 1 article (01/2016)
6.	Wang, Qiang: 1 article (01/2016)
7.	Wang, Yan: 1 article (01/2016)
8.	Xu, Ximing: 1 article (01/2016)
9.	Yu, Jiangnan: 1 article (01/2016)
10.	Zhang, Hui Yun: 1 article (01/2016)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2016 - "MTT bioassay analysis showed that HepG2 cells were the most sensitive to segetoside I compared with other cancer cell lines, with lower toxicity in healthy mouse embryonic fibroblast cells. " 01/01/2016 - "Segetoside I, a plant-derived bisdesmosidic saponin, induces apoptosis in human hepatoma cells in vitro and inhibits tumor growth in vivo." 01/01/2016 - "This development has raised an interest in the therapeutic potential of segetoside I. Here, we report the in vitro and in vivo antitumor activities of segetoside I against some selected cancer cell lines (HepG2, human hepatoma; H22, mouse hepatoma; MCF-7, breast cancer; U251, gliocoma; BGC, HGC & SGC, gastric cancinoma; Lovo-1,colon cancer). "
2.	Hepatocellular Carcinoma (Hepatoma) 01/01/2016 - "Segetoside I, a plant-derived bisdesmosidic saponin, induces apoptosis in human hepatoma cells in vitro and inhibits tumor growth in vivo." 01/01/2016 - "This development has raised an interest in the therapeutic potential of segetoside I. Here, we report the in vitro and in vivo antitumor activities of segetoside I against some selected cancer cell lines (HepG2, human hepatoma; H22, mouse hepatoma; MCF-7, breast cancer; U251, gliocoma; BGC, HGC & SGC, gastric cancinoma; Lovo-1,colon cancer). "
3.	Colonic Neoplasms (Colon Cancer) 01/01/2016 - "This development has raised an interest in the therapeutic potential of segetoside I. Here, we report the in vitro and in vivo antitumor activities of segetoside I against some selected cancer cell lines (HepG2, human hepatoma; H22, mouse hepatoma; MCF-7, breast cancer; U251, gliocoma; BGC, HGC & SGC, gastric cancinoma; Lovo-1,colon cancer). "
4.	Breast Neoplasms (Breast Cancer) 01/01/2016 - "This development has raised an interest in the therapeutic potential of segetoside I. Here, we report the in vitro and in vivo antitumor activities of segetoside I against some selected cancer cell lines (HepG2, human hepatoma; H22, mouse hepatoma; MCF-7, breast cancer; U251, gliocoma; BGC, HGC & SGC, gastric cancinoma; Lovo-1,colon cancer). "

Related Drugs and Biologics

1.	Saponins